Stock market announcement archive

LIFE: Lifecare (Life) recieves regulatory approval for first-in-human Clinical Pilot Evaluation

February 15, 2021
Bergen, February 15th, 2021 - Lifecare AS (LIFE) Lifecare has received regulatory approval for the first-in-human SencellClinical Study Protocol from the German Federal Institute for Drugs and MedicalDevices (BfArM). With this final remaining approval, Lifecare has reached itsgoal to have clinical pilot trial permission as planned in Q1 2021. Lifecare CEO Joacim Holter says, "With […]
Read more

LIFE: Financial calendar

February 15, 2021
Financial calendar for Lifecare ASFINANCIAL YEAR 202105.08.2021 - Half-yearly Report20.04.2021 - Annual Report07.05.2021 - Annual General MeetingThis information is published pursuant to the requirements set out in theContinuing obligations.
Read more

Regarding Share Transfere AGreement Human Data – Evergreen 20.10.20

October 20, 2020
Stock Market announcement Bergen, Norway – October 20, 2020: The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in the German company Digital Diagnostics AG, which has developed an accurate and reliable rapid test for Covid-19. Bionovate Technologies Corp. (BIIO), a swiss based company traded at Nasdaq OTC Foreign, has announced a Share […]
Read more

Lifecare – clearification regarding core technology 13.10.20

October 13, 2020
Following the value decrease of the Lifecare (LIFE-ME) share at Oslo Stock Exchange/Merkur Market Monday 12 October 2020 the company has received questions from shareholders and wants to clarify: There are no changes in relation to Lifecare’s patented core sensor technology, Sencell, either alone or in relation to our partners Digital Diagnostics AG or the […]
Read more

Lifecare participating in research project awarded EUR 3,9 million from the EU Commission for development …(Note: This headline has been truncated)

October 5, 2020
Lifecare participating in research project awarded EUR 3,9 million from the EU Commission for development of a bionic invisible pancreas to FORGETDIABETES. Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid […]
Read more

LIFE-ME: Lifecare AS (LIFE-ME) – Increase of share capital following exercise of share option program and share sale by close associate to primary insider

September 25, 2020
Reference is made to the stock exchange announcement by Lifecare AS (the Company) August 6th, 2020 regarding the exercise of 325.826 share options with a strike price of NOK 0,40 per share option, by Islay Venture GmbH - a company controlled by the Company CSO Prof. Dr. Dr. med Andreas Pfützner. Based on authorization granted […]
Read more

LIFE-ME: Lifecare appoints CEO

September 7, 2020
The board of directors of Lifecare has appointed Joacim Holter as CEO for Lifecare with immidiate effect. Holter have been a member of the Lifecare BoD since 2011 and was the Chairman of the BoD from 2012 to 2016. Holter has solid experience from leading international companies from the R&D stage to a commercial operation. […]
Read more

Lifecare – Corona antigen rapid test approved for clinical study – 25.08.20

August 25, 2020
Lifecare’s partner Digital Diagnostics AG has received approval for clinical tests from the responsible ethics committee and the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. This is a decisive regulatory step in the ongoing regulatory process for the Digid Cantisense™ SARS-CoV-2 test in Germany. The Digid Cantisense ™ SARS-CoV-2 antigen test for […]
Read more

Lifecare AS (LIFE-ME) – Exercise of options by primary insider – 06.08.2020

August 6, 2020
Lifecare’s Chief Scientific Officer, Prof. Dr. Dr. med Andreas Pfützner, hold share option rights both personally and through his company Islay Ventures GmbH. The share option agreement with Islay Ventures GmbH includes 521.321 share options in total and the exercise right is based on a detailed milestone plan. In addition, Islay Ventures GmbH hold 578.125 […]
Read more

Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germany for corona virus rapid test …(Note: This headline has been truncated)

June 15, 2020
Lifecare’s partner Digital Diagnostics AG seeks additional approval in Germany for corona virus rapid test – plan for scaling capacities with production partners in USA and Europe and aim to bring test to the market in millions. The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in Digital Diagnostics AG which has developed […]
Read more